Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hánah N Rier

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Oncologist|July 15, 2016
The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the LiteratureHánah N Rier, Agnes Jager, Stefan Sleijfer, et al.
Breast Cancer Research and Treatment|November 18, 2017
Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancerHánah N Rier, Agnes Jager, Stefan Sleijfer, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapyHánah N Rier, Agnes Jager, Stefan Sleijfer, et al.
Leukemia & Lymphoma|March 14, 2020
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphomaHánah N Rier, Hardjit Kharagjitsing, Joost van Rosmalen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 17, 2017
Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatmentHánah N Rier, Agnes Jager, Marieke C Meinardi, et al.
The Oncologist|July 21, 2022
Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with CancerHánah N Rier, Marieke C Meinardi, Joost van Rosmalen, et al.
Pharmaceuticals (Basel, Switzerland)|January 13, 2021
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer PatientsLeni van Doorn, Marie-Rose B S Crombag, Hánah N Rier, et al.
The Oncologist|May 24, 2017
First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based TherapyHánah N Rier, Mark-David Levin, Joost van Rosmalen, et al.
International Journal of Cancer|April 11, 2022
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fractionNathalie I Bouwer, Tessa G Steenbruggen, Hánah N Rier, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Oncologist|July 15, 2016
The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the LiteratureHánah N Rier, Agnes Jager, Stefan Sleijfer, et al.
Breast Cancer Research and Treatment|November 18, 2017
Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancerHánah N Rier, Agnes Jager, Stefan Sleijfer, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapyHánah N Rier, Agnes Jager, Stefan Sleijfer, et al.
Leukemia & Lymphoma|March 14, 2020
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphomaHánah N Rier, Hardjit Kharagjitsing, Joost van Rosmalen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 17, 2017
Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatmentHánah N Rier, Agnes Jager, Marieke C Meinardi, et al.
The Oncologist|July 21, 2022
Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with CancerHánah N Rier, Marieke C Meinardi, Joost van Rosmalen, et al.
Pharmaceuticals (Basel, Switzerland)|January 13, 2021
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer PatientsLeni van Doorn, Marie-Rose B S Crombag, Hánah N Rier, et al.
The Oncologist|May 24, 2017
First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based TherapyHánah N Rier, Mark-David Levin, Joost van Rosmalen, et al.
International Journal of Cancer|April 11, 2022
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fractionNathalie I Bouwer, Tessa G Steenbruggen, Hánah N Rier, et al.
Pageof 1